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Background: To prospectively assess circulating tumor cell (CTC) status at baseline (CTCBL) and after one cycle of a
new line of systemic therapy (CTC1C), and changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) for their utility in
predicting response, progression-free (PFS) and overall survival (OS) in metastatic breast cancer (MBC).
Methods: CTCBL and CTC1C status was determined as negative (−) or positive (+) for < 5 or ≥ 5 CTCs/7.5 ml blood
using CellSearch™ (Veridex). CTCKIN was categorized as favorable (CTC1C−) or unfavorable (CTC1C+). Tumor response
was to be assessed every 2–3 months using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Statistical analysis focused on the relation between CTC status and CTCKIN, and response, PFS, and OS.
Results: 133/393 (34%) patients enrolled were CTCBL+. CTC1C status after one cycle and radiological tumor response
were assessed after median (range) periods of 1.2 (0.5–3.2) and 2.9 (0.5–4.8) months, respectively. 57/201 (28%)
were CTC1C+. Median [95% confidence interval] PFS and OS (months) were significantly reduced in CTCBL+ vs.
CTCBL− patients (PFS 4.7 [3.7–6.1] vs. 7.8 [6.4–9.2]; OS 10.4 [7.9–15.0] vs. 27.2 [22.3–29.9]), and for CTC1C+ vs. CTC1C−
patients (PFS 4.3 [3.6–6.0] vs. 8.5 [6.6–10.4]; OS 7.7 [6.4–13.9] vs. 30.6 [22.6–not available]). Unfavorable CTCKIN was
significantly associated with progressive disease. Multivariate Cox regression analysis revealed prognostic factors for
shorter PFS (CTCBL+, persistent CTCs after one cycle, ≥ 3rd-line therapy, and triple-negative receptor status) and shorter
OS (CTCBL+, persistent CTCs after one cycle, bone-and-visceral/local metastases, ≥ 3rd-line therapy, and triple-negative
receptor status).
Conclusions: CTCBL, CTC1C, and CTCKIN are predictive of outcome in MBC. Serial CTC enumeration is useful in tailoring
systemic treatment of MBC.
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Apart from the expression of hormone and human epider-
mal growth factor receptors there are as yet hardly any
predictive factors for treatment efficacy in patients with
metastatic breast cancer (MBC) despite a rapidly growing
number of treatment options. In this situation it is of ut-
most importance to identify early indicators of response to
systemic treatment to avoid unnecessary exposure to inef-
fective but toxic therapies and to enable prognostication
of progression-free survival (PFS) and overall survival
(OS). Circulating tumor cells (CTCs) have been detected
in 40–60% of patients with MBC using the CellSearch™ sys-
tem (Veridex) [1,2]. The presence of CTCs at levels≥ 5/7.5 ml
peripheral blood is associated with decreased PFS and OS
[2-4]. It has been suggested that CTCs provide more clin-
ically relevant information than conventional imaging
studies regarding therapeutic efficacy and ultimate out-
come [5]. In addition, the prognostic information
of ≥ 5 CTCs/7.5 ml blood might be helpful in identifying
those patients who would likely experience a worse outcome
with standard treatment and might benefit from more ag-
gressive therapy [4]. Thus far, several retrospective and a
few prospective studies in patients with MBC have dem-
onstrated the usefulness of monitoring therapeutic efficacy
by serial CTC enumerations [6-9]. To further address this
important issue, the present study aimed to prospectively
assess in a large group of patients whether CTC status at
baseline (CTCBL) and after one cycle of a new line of treat-
ment (CTC1C) and changes in CTC status from baseline to
completion of one treatment cycle (CTC kinetics, CTCKIN)
could serve as early predictors of efficacy in terms of re-
sponse, PFS, and OS.
Methods
Patients and study design
This was a prospective, single-center, non-randomized,
partially blinded, treatment-based study. The study was
blinded in the following respects. Both patients and treating
physicians were blinded to CTC status, and hence treat-
ment regimens did not depend on CTC status. All investi-
gators and technical staff who performed or reviewed the
CTC studies were blinded to patient history and treatment.
CTC enumeration and characterization were confirmed by
independent reviewers. All radiologists performing com-
puted tomography (CT) scans and magnetic resonance im-
aging (MRI) studies were blinded to the patient’s treatment
regimen. The study was conducted at the National Center
for Tumor Diseases (NCT), Heidelberg, Germany and the
Department of Obstetrics and Gynecology, University of
Heidelberg, Heidelberg, Germany.
Patients included in the study were women with MBC
about to start a new line of systemic treatment. Patients
were enrolled consecutively between March 2010 and
December 2013. Main eligibility criteria were clinicaland radiological evidence of measurable or evaluable
metastatic disease according to the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria [10], age
> 18 years, progressive metastatic disease, CTC assessment
at baseline, and written informed consent. Before starting
a new line of systemic treatment, patients underwent CTC
enumeration to determine CTCBL status, defined as posi-
tive (CTCBL+) for ≥ 5 CTC or negative (CTCBL−) for < 5
CTC per 7.5 ml of peripheral blood [11]. Determination of
CTC status was repeated after the first cycle of treatment
(CTC1C). After approx. 3 months, patients were evaluated
for response by CT and MRI, as appropriate. Response
was defined as complete response (CR), partial response
(PR), stable disease (SD), and progressive disease (PD) ac-
cording to the RECIST criteria, version 1.1 [10]. Evaluation
was repeated according to the RECIST criteria every 2–3
months until progression of disease. Survival status was
recorded until death or loss to follow-up.
All study procedures, including laboratory evaluations,
imaging studies, and treatment planning, were carried out
at the NCT, Heidelberg, Germany and the Department of
Obstetrics and Gynecology of the University of Heidelberg,
Heidelberg, Germany in collaboration with the German
Cancer Research Center (DKFZ), Heidelberg, Germany,
the Department of Tumor Biology, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany, and the
Heidelberg Institute for Stem Cell Technology and Experi-
mental Medicine (HI-STEM), Heidelberg, Germany. Eth-
ical approval was obtained from the Ethics Committee of
the Medical Faculty of the University of Heidelberg.
CTC enumeration
For CTC enumeration, 7.5 ml peripheral whole blood was
collected in a standard 10-ml tube containing ethylenedi-
aminetetraacetic acid (EDTA) and a cellular preservative.
Blood samples were kept at room temperature for ≤ 72
hours before analysis using the CellSearch™ assay (Cell-
Search™ Epithelial Cell Kit/CellSpotter™ Analyzer, Veridex
LLC, Raritan, NJ, USA). Sample processing and analysis
were done strictly according to the manufacturer’s instruc-
tions. The assay uses a ferrofluid coated with antibodies
to epithelial cell adhesion molecule (EpCAM) to immu-
nomagnetically separate cells of epithelial origin from
blood, and fluorescent staining to differentiate between
debris, hematopoietic cells, and epithelial-derived circu-
lating tumor cells [12]. It provides high intra-observer,
inter-observer and inter-instrument agreement [2,13].
Thus, CTCs enumerated and characterized in this study
were cells with positive nuclear staining expressing cyto-
keratin (CK) 8, 18, and 19, and lacking CD45 [11,14].
Assay operators were trained to classify images gener-
ated by the CellSpotter™ Analyzer before study initiation.
Samples with < 5 CTCs/7.5 ml were classified as CTC−,
those with ≥ 5 CTCs/7.5 ml as CTC+ [11]. CTC kinetics
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from CTCBL to CTC1C and categorized as favorable
(CTCBL− to CTC1C− and CTCBL+ to CTC1C−) or un-
favorable (CTCBL− to CTC1C+ and CTCBL+ to CTC1C+).
HER2 status
Human epidermal growth factor receptor 2 (HER2) sta-
tus was determined using the immunohistochemistry-
based HERCEP™ test (DAKO, Glostrup, Denmark) for
semi-quantitative detection of HER2 expression in breast
cancer tissue. Expression of HER2 was scored on a scale
from 0 to 3+. Tissue samples with a score of 3+ were
considered HER2-positive. Whenever the score was 2+,
HER2 amplification was determined by fluorescence in-
situ hybridization using the Pathvysion Kit (Vysis Inc.,
Downers Grove, IL, USA).
Data analysis and statistics
Patient demographic and clinical characteristics were
summarized as medians and ranges or numbers and per-
centages, as appropriate. The numbers of missing values
were given in ‘no data’ categories. Differences between
the CTC+ and CTC− groups were compared using the
Wilcoxon rank test and Fisher’s exact test, as appropri-
ate. PFS was defined from date of enrollment until the
date of disease progression or death from any cause,
whichever occurred first. OS was calculated from the
date of enrollment until the date of death from any
cause. Patients who were alive or showed no progression
at last follow-up were regarded as censored observations.
Median follow-up time was calculated using the reverse
Kaplan-Meier method.
To identify predictors of PFS and OS, the following can-
didate predictors were selected a priori based on previous
studies and univariate analysis: CTCBL status (negative or
positive), age at study entry, molecular subtypes (hormone
receptor (HR)+/HER2−, HER2+, or triple negative breast
cancer (TNBC)), site of metastasis (local, bone/visceral, or
both), number of metastatic sites (one or at least two), and
line of therapy (first, second, or at least third). The prog-
nostic effects of these factors were determined by multivari-
ate analysis using a Cox proportional hazards regression
model. Patients with missing values in these variables were
not included in the Cox regression models. Separate
models for CTCBL and CTCKIN were formulated because
the CTCBL model showed a fairly larger sample size and to
avoid multicollinearity (since CTCBL and CTCKIN are re-
lated). Concordance indices were used to estimate the pre-
dictive accuracy of the Cox models.
During the initial phase of the study, which comprised
the first 100 patients, CTC1C status was routinely deter-
mined only in CTCBL+ patients and not in CTCBL− pa-
tients. However, as preliminary CTC1C results from
CTCBL− patients also drew interest, it was decided todetermine CTC1C status in all subsequent patients. This
change may have introduced a potential source of bias in
the CTC1C results, e.g. proportions. All CTCKIN findings
were, thus, conditioned on survival up to the determin-
ation of CTC1C status.
Statistical analyses were performed using R (version
3.0.0, package survival). All reported P values were two-
sided and a significance level of 5% was chosen.Results
Patients and study design
From March 2010 through December 2013, 403 consecu-
tive patients were enrolled in the study. Figure 1 shows
the flow of patients through the study. Reasons for exclu-
sion from, or non-availability for, further analysis are de-
tailed in the figure legend. Of the 393 evaluable patients
with CTCBL counts, 133 (34%) were CTCBL+ and 260
(66%) were CTCBL−. The two patient groups did not differ
significantly in median age (range) at initial diagnosis of
breast cancer (50 (28–81) vs. 51 (23–79) years) but age at
study entry was significantly lower in CTCBL+ patients (57
(33–81) vs. 61 (29–89) years). Patient characteristics at
baseline and after one cycle of treatment are summarized
in Table 1. Notably, the majority of patients had ER+ (271/
378 (72%)), PgR+ (240/370 (65%)), and HER2− (274/341
(80%)) primary tumors. Most patients had more than one
metastatic site (305/393 (78%)) and approximately half of
patients had both bone and visceral/local metastases (191/
393 (49%)). At study entry, 135/391 (35%) patients were
about to start third- or higher-line treatment.CTC status and response
CTC1C status was assessed after a median (range) of 1.2
(0.5–3.2) months. CTC1C status was positive in 57/201
(28%) and negative in 144/201 (72%) of patients. During
the initial phase of the study, which comprised the first
100 patients, CTC1C status was determined only in
CTCBL+ patients. As shown in Table 1, at least SD (i.e.
CR, PR, or SD) was seen in 162/255 (64%) patients at
the 3-month radiological examination, of whom 52/162
(32%) were CTCBL+ while 110/162 (68%) were CTCBL−.
Radiological restaging was performed a median of 2.9
(0.5–4.8) months after study entry. PD occurred in 93/
255 (36%) patients, of whom 40/93 (43%) were CTCBL+
while 53/93 (57%) were CTCBL− (Fisher’ exact test, P =
0.104). CTCKIN could be determined in 201 patients as
both their CTCBL and CTC1C data were available. At least
SD was achieved in 55/75 (73%) patients with CTCKIN
from CTCBL− to CTC1C−, 21/32 (66%) with CTCKIN
from CTCBL+ to CTC1C−, 20/41 (49%) with CTCBL+ to
CTC1C+, and 3/6 (50%) with CTCBL− to CTC1C+ (Fisher’s
exact test, P = 0.04997).
Figure 1 Flow of patients through the study. Of 403 consecutive patients assessed for eligibility, 10 (2.5%) were excluded from the study
because essential data items were not available (no clinical data: 1 patient; no CTCBL data: 9 patients). Of the 393 patients included in the study,
192 had no CTC1C counts and were therefore excluded from further analysis for the following reasons. During the initial phase of the study,
i.e. the first 100 patients, CTC1C status was routinely determined only in CTCBL+ patients, resulting in 64 CTC1C− patients without CTC1C counts.
Of the remaining 128 patients without CTC1C counts, 12 were excluded because blood samples were not obtained within the predefined study
timeframe of 0.5–3.2 months, 25 did not survive to CTC1C assessment because they died within the first 3.2 months, and 91 patients who
survived beyond 3.2 months after inclusion had no CTC1C count (41 had not yet proceeded to CTC1C and 50 were lost to follow-up blood
sampling as our center often treats external patients).
Wallwiener et al. BMC Cancer 2014, 14:512 Page 4 of 12
http://www.biomedcentral.com/1471-2407/14/512CTC status and survival
Follow-up data were available for 356 patients with a
median [95% CI] follow-up of 26.0 [23.7–28.5] months
for OS.
Figure 2 shows Kaplan-Meier plots for PFS and OS by
CTC status at baseline (CTCBL, top panels) and after the
first cycle of a new line of systemic therapy (CTC1C, bot-
tom panels). Median [95% CI] PFS and OS were signifi-
cantly shorter in CTCBL+ than in CTCBL− patients (PFS:4.7 [3.7–6.1] vs. 7.8 [6.4–9.2] months, P = 0.001; OS: 10.4
[7.9–15.0] vs. 27.2 [22.3–29.9] months, P < 0.001). Median
[95% CI] PFS and OS were also significantly shorter in
CTC1C+ than in CTC1C− patients (PFS: 4.3 [3.6–6.0] vs.
8.5 [6.6–10.4], P < 0.001; OS: 7.7 [6.4–13.9] vs. 30.6
[22.6–na], P < 0.001).
Figure 3 shows Kaplan-Meier plots for PFS and OS
stratified by change in patients’ CTC status from base-
line to completion of the first treatment cycle (CTCKIN).
Table 1 Patient characteristics by CTC+ status at baseline (BL) and after one cycle of treatment (1C)
All patients, BL CTCBL+ P All patients, 1C CTC1C+ P
Patients 393 133 (34%)* 201 57 (28%)
Age, median (range); years
at initial diagnosis 51 (23–81) 50 (28–81) 0.853 50 (28–77) 50 (33–77) 0.570
at study inclusion 59 (29–89) 57 (33–81) 0.030 57 (33–89) 55 (33–77) 0.092
Baseline CTC count, median (range); number/7.5 ml blood 1 (0–930) 21 (5–930) — —
ER status 0.631 0.729
ER+ 271 94 (35%) 136 41 (30%)
ER− 107 34 (32%) 55 15 (27%)
No data 15 5 (33%) 10 1 (10%)
PgR Status 0.819 0.866
PgR+ 240 81 (34%) 124 36 (29%)
PgR− 130 46 (35%) 64 20 (31%)
No data 23 6 (26%) 13 1 (8%)
HER2 status of primary tumor 0.119 0.028
HER2+ 67 18 (27%) 30 4 (13%)
HER2− 274 102 (37%) 142 49 (35%)
No data 52 13 (25%) 29 4 (14%)
Molecular subtypes 0.221 0.062
HR+/HER2− 216 83 (38%) 110 39 (35%)
HER2+ 67 18 (27%) 30 4 (13%)
TNBC 57 19 (33%) 32 10 (31%)
No data 53 13 (25%) 29 4 (14%)
Metastasis site < 0.001 0.005
Bone 68 25 (37%) 40 16 (40%)
Visceral/local 134 28 (21%) 68 10 (15%)
Both 191 80 (42%) 93 31 (33%)
No data 0 0 (0%) 0 0 (0%)
Number of metastasis sites 0.372 1.000
1 88 26 (30%) 48 14 (29%)
≥ 2 305 107 (35%) 153 43 (28%)
No data 0 0 (0%) 0 0 (0%)
Line of therapy 0.724 0.097
1 175 62 (35%) 97 26 (27%)
2 81 28 (35%) 44 8 (18%)
≥ 3 135 42 (31%) 59 22 (37%)
No data 2 1 (50%) 1 1 (100%)
Treatments before study
Hormonal therapy 0.904 0.167
Yes 289 97 (34%) 143 45 (31%)
No 104 36 (35%) 58 12 (21%)
No data 0 0 (0%) 0 0 (0%)
Antibody therapy (bevacizumab or other) 0.210 0.023
Yes 103 47 (46%) 54 22 (41%)
No 288 86 (30%) 146 35 (24%)
No data 2 0 (0%) 1 0 (0%)
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Table 1 Patient characteristics by CTC+ status at baseline (BL) and after one cycle of treatment (1C) (Continued)
Anti HER2 therapy (trastuzumab, lapatinib) 0.012 0.027
Yes 81 18 (22%) 37 5 (14%)
No 311 115 (37%) 163 52 (32%)
No data 1 0 (0%) 1 0 (0%)
Chemotherapy 0.022 0.054
Mono-CHT 87 24 28%) 39 8 (21%)
Poly-CHT 109 35 (32%) 64 18 (28%)
Bevacizumab + CHT 93 44 (49%) 47 21 (45%)
Other CHTs 41 9 (22%) 22 3 (14%)
No CHT 62 21 (34%) 28 7 (25%)
No data 1 0 (0%) 1 0 (0%)
Radiological response after first cycle of chemotherapy 0.104 0.011
CR/PR/SD 162 52 (32%) 99 23 (23%)
PD 93 40 (43%) 55 24 (44%)
No data 138 41 (30%) 47 10 (21%)
*Percentages of the respective row total for baseline and first-cycle data.
CHT, chemotherapy; CR, complete response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PD, progressive
disease; PgR, progesterone receptor; PR, partial response; SD, stable disease; TNBC, triple negative breast cancer.
P-values were calculated for differences between CTC+ and CTC− groups using the Wilcoxon test or Fisher’s exact test, as appropriate. Bold P values indicate
statistical significance.
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ing on CTCKIN (P < 0.001 for PFS and OS). For PFS, we
simplified to favorable and unfavorable CTCKIN, depend-
ing on CTC1C status. PFS for patients with favorable
CTCKIN (i.e. CTCBL− to CTC1C− or CTCBL+ to CTC1C−)
did not differ significantly (P = 0.251). Similarly, PFS for
unfavorable CTCKIN (i.e. CTCBL− or CTCBL+ to CTC1C+)
also showed no significant difference (P = 0.665). Regard-
ing OS, CTCBL status also appeared important since pa-
tients with CTCKIN from CTCBL− to CTC1C− lived
significantly longer than those with CTCKIN from CTCBL+
to CTC1C− (P = 0.049). OS times for unfavorable CTCKIN
did not differ significantly (P = 0.358). When conditioning
on non-missing CTC1C values, the median OS time was
overestimated by 2.7 months for CTCBL+ and 3.4 months
for CTCBL− patients. This provides a rough estimate of
the effect of deaths before CTC1C. No CTC1C status was
obtained for 12/12, 8/10, and 5/13 patients who died dur-
ing the first, second, and third month after study entry, re-
spectively. No CTC1C status was obtained for 26/40, 3/5,
and 0/6 patients who were censored during the first, sec-
ond, and third month after study entry, respectively.
Table 2 summarizes the results for PFS, OS, and progres-
sion by CTCKIN.
Response and survival
Survival depended significantly on the result of radiological
assessment 3 months after inclusion as median [95% con-
fidence interval (CI)] OS times were 29.9 [27.4–37.1]
months for patients who achieved at least SD, and 13.6
[9.1–16.4] months for patients with PD (n = 356; P < 0.001).Multivariate regression analysis
Table 3 shows the result of multivariate regression ana-
lysis for PFS and OS using a Cox proportional hazards
model including CTCBL, age at study entry, number of
metastatic sites, site of metastasis, line of therapy, and
molecular subtypes. Significant risk factors for progres-
sion were CTCBL+ status, third or higher line of therapy,
and TNBC. Significant risk factors for death were
CTCBL+, both visceral/local and bone metastases, third
or higher line of therapy, and TNBC. The concordance
index was 0.62 for the PFS Cox model and 0.71 for the
OS Cox model.
Table 4 shows the result of multivariate regression ana-
lysis for PFS and OS using a Cox proportional hazards
model including CTCKIN. In this model, significant risk
factors for both progression and death were CTCBL+ to
CTC1C+ kinetics, line of therapy, and TNBC. The pres-
ence of both visceral/local and bone metastases was an
additional significant risk factor for OS. The concordance
index was 0.67 for the PFS and 0.80 for the OS Cox
model.
Discussion
In recent years, several retrospective and a few prospective
studies have demonstrated the strong and independent
prognostic role of CTCs in MBC [1,2,4,9,11,15]. Using the
FDA-cleared CellSearch™ system, detection of ≥ 5 CTCs/
7.5 ml blood before starting a new line therapy is asso-
ciated with decreased PFS and OS. In addition, CTCs
provide an effective prognostic tool for early response
prediction as survival is prolonged once counts ≥ 5
Figure 2 Progression-free survival and overall survival by CTC status. PFS (left) and OS (right) by CTC status at baseline (top) and after the
first cycle of a new line of systemic therapy (bottom) in 356 patients with MBC.
Figure 3 Progression-free survival and overall survival by CTCKIN. PFS (left) and OS (right) stratified by change in CTC status (CTCKIN) from
baseline to completion of the first treatment cycle.
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Table 2 CTCKIN and association with PFS, OS, and progression at 3-month radiological examination
CTCBL (baseline) CTC1C (after 1st cycle) PFS (months) OS (months) Progression
Median [95% CI] Median [95% CI] Numbers (percentage)
Favorable Negative (CTCBL−) Negative (CTC1C−) 8.7 [6.6–11.5] 30.6 [27.4–na] 20/75 (27%)
Positive (CTCBL+) Negative (CTC1C−) 8.0 [5.5–12.1] 16.7 [13.6–na] 11/32 (34%)
Unfavorable Positive (CTCBL+) Positive (CTC1C+) 4.3 [3.6–6.1] 7.7 [6.1–13.1] 21/41 (51%)
Negative (CTCBL−) Positive (CTC1C+) 3.7 [2.5–na] 14.0 [5.7–na] 3/6 (50%)
na = not available.
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CTC positive to CTC negative [4,7,9,16]. Thus, serial CTC
enumeration promises to provide a fast and easy-to-
perform tool for monitoring the efficacy of a given sys-
temic treatment in MBC patients [7]. To address this dir-
ectly in a clinical setting, the present large study analyzed
the changes in CTC status, or CTC kinetics, occurring
from baseline to completion of the first cycle of a new line
of systemic therapy in patients with MBC. The data were
then analyzed to prospectively determine the associationTable 3 Cox proportional hazards model with CTCBL
PFS
Hazard ratio 95% CI
Baseline CTC status (CTCBL)
< 5 CTC (CTCBL−) 1.00
≥ 5 CTC (CTCBL+) 1.55 1.19–2.01
Age at inclusion
Per year 0.99 0.98–1.00
Number of metastatic sites
One site 1.00













Bold P values indicate statistical significance.
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, tripof CTC status and first-cycle CTC status with treatment
response, PFS, and OS.
Our data demonstrate that patients with favorable
CTC kinetics, i.e. those whose CTC status after one
cycle of therapy (CTC1C) was negative, were more likely
to respond to therapy as determined by RECIST criteria
than patients with persistently high CTC counts [5,8,16,17].
Furthermore, PFS was significantly longer in patients
with a negative CTC1C status than in those who were
CTC positive after completing the first treatment cycle.OS
P Hazard ratio 95% CI P
1.00
0.001 2.79 2.04–5.63 < 0.001
0.207 1.00 0.99–1.01 0.938
1.00
0.892 0.71 0.41–1.23 0.227
1.00
0.939 1.75 1.00–3.01 0.052
0.739 2.55 1.41–4.60 0.002
1.00
0.113 1.45 0.92–2.28 0.112
< 0.001 2.01 1.37–2.96 < 0.001
1.00
0.577 1.09 0.72–1.63 0.695
< 0.001 2.86 1.91–4.27 < 0.001
le negative breast cancer.
Table 4 Cox proportional hazards model with CTCKIN
PFS OS
Hazard ratio 95% CI P Hazard ratio 95% CI P
CTCKIN
CTCBL− to CTC1C− 1.00 1.00
CTCBL+ to CTC1C− 1.01 0.62–1.64 0.981 1.68 0.85–3.32 0.135
CTCBL+ to CTC1C+ 2.17 1.39–3.37 < 0.001 5.58 3.06–10.15 < 0.001
CTCBL− to CTC1C+ 2.17 0.91–5.14 0.079 2.56 0.76–8.00 0.134
Age at inclusion
Per year 0.99 0.98–1.00 0.333 0.99 0.97–1.01 0.284
Number of metastatic sites
One site 1.00 1.00
Multiple sites 0.94 0.98–1.01 0.832 0.59 0.24–1.48 0.260
Site of metastasis
Bone 1.00 1.00
Visceral/local 1.10 0.59–2.04 0.768 2.12 0.82–5.49 0.124
Both 1.27 0.68–2.37 0.449 3.35 1.27–8.82 0.014
Line of therapy
1 1.00 1.00
2 1.66 1.00–2.75 0.049 2.01 1.02–3.99 0.045
≥ 3 2.49 1.58–3.94 < 0.001 2.49 1.32–4.65 0.004
Molecular Subtypes
HR+/HER2− 1.00 1.00
HER2+ 1.34 0.81–2.19 0.252 1.37 0.64–2.91 0.418
TNBC 2.58 1.53–4.35 < 0.001 3.92 2.11–7.30 < 0.001
Bold P values indicate statistical significance.
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
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baseline, supporting the role of serial CTC enumeration
as a means of assessing treatment response. Accord-
ingly, multivariate analysis showed no impact of a posi-
tive baseline CTC status on PFS if CTC status turned
negative after one cycle of treatment. Budd et al. found
CTC assessment to be predictive of survival in both pa-
tients with and without radiological progression [5].
They also suggested that CTC assessment might have ad-
vantages over radiographic evaluation, including higher re-
producibility due to lower interreader variability, useful
results at an earlier time, and more robust prediction of
survival [5]. Imaging studies, currently the gold standard
surrogate for clinical benefit from systemic therapy, are
usually not performed before completion of at least two or
three cycles of therapy. Hence, CTC determination after
one cycle might enable much earlier assessment of treat-
ment response and thus spare patients the unnecessary
side effects of ineffective but toxic treatments. Moreover,
radiographic imaging is confounded by a considerable de-
gree of intraobserver and interobserver variability, whereas
CTC enumeration with the CellSearch™ system is highly
standardized [18].In the current study, the majority of patients (66%)
were CTC negative at baseline. This is in contrast to a
seminal analysis provided by Cristofanilli et al. [2], who
reported 70% of the patients harboring ≥ 5 CTCs/7.5 ml
blood. However, in our study, only 31% of patients re-
ceived third- or higher-line therapy. Thus, the difference
might be due to a selection bias.
Other explanations, however, are also conceivable. Des-
pite the prognostic impact of CellSearch CTC in MBC, it
has become clear that this technology has limitations. In
particular, it is not capable of detecting the entire, highly
heterogeneous population of CTCs as it involves EpCAM-
based capturing methods [19]. Moreover, a recent retro-
spective study in 292 MBC patients reported that the
probability of undetectable CTCs was increased in pa-
tients with negative hormone receptors, high tumor grade,
triple-negative disease, and inflammatory breast cancer
[20]. The authors suggested that these findings might
reflect underestimation of CTCs by CellSearch due partly
to CTCs undergoing epithelial-mesenchymal transition
(EMT). An earlier study found that a major proportion of
CTCs in the blood of MBC patients showed EMT and
tumor stem cell characteristics and that such CTCs were
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hand, it has recently been demonstrated that not all pa-
tients with detectable CTCs have a poor prognosis, sug-
gesting that further characterization of these cells might
provide more information on their biologic significance.
In this regard, Smerage et al. [22] used CellSearch to
analyze CTC apoptosis and Bcl-2 expression and show
that determination of these markers may have biological
and clinical implications. This, therefore, might also offer
a further explanation for the large proportion of CTC
negative patients in the present study. Moreover, thera-
peutic regimens might also explain the high CTC negativ-
ity rate. A combination of e.g. trastuzumab and lapatinib
might be more effective in HER2 positive patients and
even stem cell-like cells might be eliminated by such
a combination.
In our study, patients with a negative CTC status after
the first cycle had a significantly prolonged OS if they were
CTC negative at baseline. This observation is in line with
results reported by Pierga et al. [9], showing that OS was
better in patients with persistently low CTC counts (< 5
CTCs/7.5 ml blood) than in initially CTC positive patients
with low CTC counts after one treatment cycle. In
addition, it indicates that baseline CTC determination en-
ables identification of more aggressive disease and thus
may be valuable in making an early decision whether pa-
tients require more aggressive or less aggressive treatment
[15]. Of note, the group of baseline positive patients in
our study was significantly younger than the baseline
negative patients at the time of study entry, although there
was no significant difference with respect to age at initial
diagnosis. This further supports the hypothesis that higher
CTC counts may be suggestive of more aggressive disease
in younger women.
Advantages of the CellSearch™ system include semi-
automation and proven reproducibility, reliability, sen-
sitivity, linearity, and accuracy [13]. However, it is im-
portant to bear in mind that 66% of MBC patients in
our cohort had < 5 CTCs/7.5 ml blood at baseline. Dur-
ing the initial phase of the study, which comprised the
first 100 patients, CTC status at follow-up was only
assessed in patients who had been CTC positive at base-
line. Due to the unexpectedly low CTC positivity at
baseline, we decided also to evaluate initially CTC nega-
tive patients for CTC status at follow-up. However, only
7% of the patients who were CTC negative at baseline
were found to be CTC positive after one cycle of treat-
ment. Therefore, it seems that CTC counts, as mea-
sured by the CellSearch™ system, are useful as a tool for
monitoring treatment efficacy only in patients who are
CTC positive when they start a new line therapy, highlight-
ing the need for additional, more sensitive methods of
CTC detection. In addition, methods based on the detec-
tion of EpCAM, like the CellSearch™ system, might missCTCs that have undergone epithelial-mesenchymal transi-
tion [23].
We found a strong relationship between treatment-
associated CTC kinetics and outcome. Favorable CTCKIN
was associated with a significantly better disease con-
trol rate. In addition, patients with high baseline CTC
counts ≥ 5 CTCs/7.5 ml blood that decreased to < 5
CTCs/7.5 ml blood after one cycle of treatment had a PFS
similar to patients with baseline counts < 5 CTCs/7.5 ml
[24]. In contrast, OS depends not only on the patient’s
current CTC status, but also on her previous CTC history.
For instance a patient with a CTC1C− status had a better
prognosis if she was initially CTCBL− rather than CTCBL+.
Thus, a patient’s CTC history might better reflect the
overall aggressiveness and prognosis of her breast cancer
than the current CTC status alone. Using a somewhat dif-
ferent, CTC count-based approach to classifying CTC kin-
etics, a recent study by Hartkopf et al. demonstrated that
changes in CTC levels from baseline to completion of
three treatment cycles also correlated with radiological re-
sponse and were associated with survival [17]. Median OS
was significantly longer in patients with decreasing CTC
levels than in patients with increasing CTC counts.
Data from this and other studies [5,8,9,16,17] do not
allow the distinction between breast cancers with un-
favorable CTC kinetics that are resistant to the specific
type of chemotherapy administered versus those that
are resistant to chemotherapy in general. Ongoing pro-
spective trials such as the Southwest Oncology Group
(SWOG) protocol S0500 trial and the DETECT III trial
will help to shed light on the utility and limitations of
measuring CTCs to monitor response to treatment. The
SWOG trial randomly assigns MBC patients with per-
sistent CTC counts ≥ 5/7.5 ml blood at the follow-up
visit to either continuation of their current therapy or
switching to a different regime. DETECT III is a multicen-
ter phase III trial comparing standard therapy +/− lapatinib
in HER2 negative MBC patients but with HER2 positive
CTCs.
The potential of CTC enumeration and characterization
to serve as a “liquid real-time biopsy”, i.e. as a noninvasive
means of predicting and monitoring response to treatment
in metastatic disease, has recently been comprehensively
discussed by Alix-Panabieres and Pantel [25]. Unsuccessful
regimens could be abandoned early in favor of alternative
regimens, thus sparing patients unnecessary toxicity [6-8].
Moreover, in the future real-time CTC enumeration during
therapy should be complemented by additional markers,
which enable the monitoring of those cells which possess
the highest metastasis-inducing activity within the highly
heterogeneous pool of EpCAM+ CTCs [4,26]. For ER+ lu-
minal MBCs such metastasis-initiating cells have been
functionally defined as EpCAM+/CD44+/MET+/CD47+
[4,26]. However, novel methods have yet to be developed
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studies are needed to investigate ways in which CTC enu-
meration can be combined with computer-assisted assess-
ment of prognosis and adjuvant therapy planning based on
various biomarkers [27-29] to further individualize and
target the treatment of breast cancer, which remains the
most frequent cancer in women in Germany and world-
wide [30].
In summary, our study demonstrates that serial CTC
monitoring is a versatile tool for predicting treatment
outcome in MBC and a useful adjunct to standard diag-
nostic tests for tailoring therapy. The data presented
here further support the hypothesis that the monitoring
of CTCs is a promising source of biological information
towards predicting the course of disease and its respon-
siveness to targeted agents, hence paving the way for in-
dividualized therapy [24,25,31,32].
Conclusions
CTC status at baseline (CTCBL) and after one cycle of a
new line of therapy (CTC1C) and CTC kinetics (CTCKIN,
i.e. changes from CTCBL to CTC1C) are highly predictive
of outcome in MBC and significantly associated with
PFS and OS.
Based on the findings of the present prospective study,
we consider serial CTC monitoring a versatile tool for
predicting treatment outcome in MBC and a useful ad-
junct to standard diagnostic tests in tailoring therapy.
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